Table 7.
Distribution of Brain Molecular Markers for Select Histopathologically-Confirmed Glioma and Embryonal Tumor Histopathologies, CBTRUS Statistical Report: US Cancer Statistics – NPCR and SEER, 2018-2019
| Histopathology | Frequency (%) |
|---|---|
| Diffuse Astrocytoma | |
| 9400/3: Diffuse astrocytoma, IDH-mutant a | 1,103 (42.7%) |
| 9400/3: Diffuse astrocytoma, IDH-wildtype a | 883 (34.2%) |
| 9400/3: Diffuse astrocytoma, IDH Status Unknown | 599 (23.2%) |
| Anaplastic Astrocytoma | |
| 9401/3: Anaplastic astrocytoma, IDH-mutant a | 1,159 (43.6%) |
| 9401/3: Anaplastic astrocytoma, IDH-wildtype a | 1,167 (43.9%) |
| 9401/3: Anaplastic astrocytoma, IDH Status Unknown | 331 (12.5%) |
| Glioblastoma | |
| 9440/3: Glioblastoma, IDH-wildtype a | 18,579 (76.8%) |
| 9440/3: Glioblastoma, IDH Status Unknown | 4,398 (18.2%) |
| 9441/3: Giant cell glioblastoma | 155 (0.6%) |
| 9442/3: Gliosarcoma | 475 (2%) |
| 9445/3: Glioblastoma, IDH-mutant b | 580 (2.4%) |
| Oligodendroglioma | |
| 9450/3: Oligodendroglioma, IDH-mutant and 1 p/19q co-deleted a | 1,227 (90.8%) |
| 9450/3: Oligodendroglioma, NOS | 124 (9.2%) |
| Anaplastic Oligodendroglioma | |
| 9451/3: Anaplastic oligodendroglioma, IDH-mutant and 1 p/19q co-deleted a | 653 (93.3%) |
| 9451/3: Oligodendroglioma, anaplastic | 47 (6.7%) |
| Medulloblastoma | |
| 9470/3: Medulloblastoma, NOS | 404 (48.5%) |
| 9471/3: Desmoplastic nodular medulloblastoma | 30 (3.6%) |
| 9471/3: Medulloblastoma, SHH-activated and TP53-wildtype a | 161 (19.3%) |
| 9472/3: Medullomyoblastoma | -- |
| 9474/3: Large cell medulloblastoma | 59 (7.1%) |
| 9475/3: Medulloblastoma, WNT-activated, NOS b | 29 (3.5%) |
| 9476/3: Medulloblastoma, SHH-activated and TP53-mutant b | -- |
| 9477/3: Medulloblastoma, non-WNT/non-SHH b | 134 (16.1%) |
aCollected in NAACCR Item #3816, Brain Molecular Markers.
bNew ICD-O-3 codes implemented in 2018.
-- Cases and rates are not presented when fewer than 16 cases were reported for the specific category.
Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; US, United States; NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology, and End Results Program; NOS, not otherwise specified.